You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

April 8, 2020

Laos Issues COVID-19 Regulations for Freight, Insurance, Mineral Processing, Hydropower, and Healthcare Industries

Subscribe to Updates

Cross-Border Transportation of Goods

The National Taskforce Committee for COVID-19 Prevention and Control has issued Guideline No. 020, Regarding Prime Minister’s Order No.02/PM, dated April 2, 2020, which includes directives aimed at the freight sector. The transportation of goods is one of the few operations that is still permitted to cross the Lao border, although this is subject to the following regulations:

  • The importation of goods by vehicles is authorized up to the loading point closest to the port of entry. Once the goods have been unloaded, the vehicle must depart immediately. Before entering Laos the driver must fill out a health form and undergo an examination, as recommended by the National Taskforce Committee for COVID-19 Prevention and Control.
  • For the transportation of goods that transit through Laos before being exported to a third country, vehicles can proceed to the loading point in Laos and onward to their destination. If it is necessary to use a vehicle from the country of origin to reach the destination, the vehicle must be sprayed with a disinfectant in accordance with the specified rules. Foreign drivers are also prohibited, so the driver must be a Lao national.

Insurance Operations

On March 31, 2020, the Department of State Enterprise Investment Management and Insurance, which is under the Ministry of Finance, issued Notification No. 0338, which provides the following measures:

  • Deferment of the deadline for submission of insurance company financial reports and other reporting duties relating to the operation of insurance businesses for the year 2019. The new submission deadline is April 30, 2020.
  • Requirement for life insurance and health insurance policies that have already been sold to also cover COVID-19-related symptoms, in accordance with the amount and duration of coverage agreed upon in the contract.
  • Requirement for all insurance companies to devise a plan to form teams of employees to work in their offices from April 1 to April 19, 2020, and to support other employees to work remotely. Alternatively, companies can devise a specific schedule for each employee to come to work on an alternating basis, in order to prevent the spread of the COVID-19. Insurance companies are also requested to ensure they can receive claims while the COVID-19 outbreak measures are in place.

Factories that Process Minerals and Hydropower Plants under Construction

On April 5, 2020, the Ministry of Mines and Energy issued Notification 0432/MEM, which orders hydropower plant construction projects and factories involved in exploration for and processing of minerals to suspend their activities from April 1 to April 19.

Until April 19, these operations are required to proceed as follows:

  • Manage their staff and personnel who are currently renting and staying in accommodation within the factory, and follow measures issued by the government. Employees and personnel should not leave the factory premises, or their accommodations, if it is not necessary (a phrase that is not yet defined). Employees and personnel must be prohibited from traveling to local places where there is a risk of contracting the virus.
  • Disseminate information about COVID-19 to employees and personnel on-site in order to prevent and combat the spread of the virus, in accordance with recommendations issued by the local authorities. Any employee who displays symptoms of the virus should be separated from the other employees, and the supervisor should immediately contact the emergency number (166 or 020-5406-6777) in order to implement the recommendations issued by the National Task Force.
  • Ensure that social distancing of two meters is strictly observed by all employees, provide masks, and ensure that soap is available for washing hands, or disinfectant is provided to kill the virus, in accordance with the recommendations of the National Task Force.
  • Disinfect the premises, including production sites, canteens, and accommodations, along with other areas where there is a risk of the virus spreading.

Facilities that have been closed and adversely impacted by COVID-19 should report the impact to the Ministry of Energy and Mines, and the related authorities, as indicated in Prime Minister’s Order No. 06/PM, dated March 29, 2020. In addition, the ministry welcomes comments regarding this notification from stakeholders and from the public and private sectors.

Private Hospitals and Clinics Prohibited from Treating COVID-19

Out of a concern about some private caregiving facilities in the country being inadequately equipped to handle the epidemic, on April 2, 2020, the Ministry of Health issued Notification 0413/MOH, ordering private hospitals and treatment facilities not to attempt treatment of COVID-19 patients (with limited exceptions for international-standard private hospitals). 

This notification followed the issuance of previous measures seemingly announcing the closure of private hospitals and private treatment centers. Together, however, these regulations mean that  specialized clinics and private hospitals can provide their usual medical services, but they are not allowed to attempt treatment of COVID-19 patients; if a case of COVID-19 is suspected, they should call the emergency hotline immediately.

For more details on these measures, or on any aspect of Laos’ response to the COVID-19 pandemic, please contact Dino Santaniello at [email protected].

Related Professionals

Industries

Aviation

Energy

Insurance

Life Sciences

Practices

Corporate/M&A

Regulatory Affairs

Location

RELATED INSIGHTS​ 

September 15, 2026
Insurance specialists from Tilleke & Gibbins in Bangkok have contributed the updated Thailand chapter to the newly released 2026 edition of Thomson Reuters’ Practical Law guide to insurance and reinsurance. The Thailand chapter offers a comprehensive Q&A-style overview of the legal and regulatory framework governing insurance and reinsurance in the country. It provides key insights for businesses, insurers, reinsurers, and intermediaries operating in or entering the Thai market. Key topics covered include: Market structure and common types of insurance Regulatory framework and oversight by the Office of Insurance Commission (OIC) Authorisation requirements for insurers, reinsurers, and intermediaries Ownership restrictions and foreign investment rules Corporate governance, capital requirements, and solvency obligations Reinsurance arrangements, including fronting, risk transfer, and common contractual clauses Policy content requirements, standard clauses, and consumer protections Claims procedures, statutory time limits, and subrogation rights Dispute resolution mechanisms, including OIC arbitration and court proceedings Insolvency protections for policyholders Tax treatment of insurance and reinsurance businesses in Thailand Recent legal developments, including updated OIC regulations and insurance licensing guidelines The 2026 edition reflects Thailand’s evolving regulatory environment, including ongoing legislative reforms to strengthen corporate governance, risk-based capital requirements, and digital media compliance in the insurance sector. It also highlights practical considerations for foreign insurers, reinsurers, and intermediaries seeking to participate in Thailand’s insurance market. Tilleke & Gibbins contributes regularly to the Practical Law series of guides for various jurisdictions in Southeast Asia, providing trusted legal insight for multinational companies. Access the full Thailand chapter below. Reproduced from Practical Law with the permission of the publishers. For further information, visit practicallaw.com.
Read More
September 9, 2026
On August 5, 2026, the Consumer Case Division of Thailand’s Civil Court rendered a judgment in a case involving a beauty clinic that advertised acne scar treatments using claims that the clinic was operated by a specialist physician and that the treatment, allegedly involving stem cell technology, could permanently remove acne scars. The plaintiff brought a claim against both the physician-owner and the clinic company, alleging that the advertisements were false and induced her to purchase the treatment. The court found that the clinic was liable for the false representations and that the physician-owner, as both the authorized director of the company and the medical practitioner who provided treatment, was jointly responsible. Although the plaintiff could not fully prove all damages claimed, the court awarded compensation of THB 20,000, together with interest. While the judgment arose from a consumer protection dispute, it serves as a valuable reminder that medical facility advertisements in Thailand are regulated and may expose clinics and healthcare providers not only to regulatory enforcement but also to civil liability from patients who rely on misleading promotional claims. Regulatory Framework Governing Medical Facility Advertisements Medical facility advertising in Thailand is governed by the Medical Facility Act B.E. 2541 (1998), as amended by the Medical Facility Act (No. 4) B.E. 2559 (2016). The principal secondary legislation is the Department of Health Service Support (DoHSS) Notification Re: Rules, Procedures, Conditions, and Fees for an Advertisement or Publication Concerning a Medical Facility, which came into force on November 25, 2019. Under this notification, “advertising” includes any act, by any means, that causes members of the public to see, hear, or otherwise become aware of a message, sound, or image for the commercial benefit of a medical facility. This broad definition covers not only traditional media but also clinic websites, social
Read More
September 9, 2026
On June 30, 2026, Indonesia’s National Agency of Drug and Food Control (BPOM) issued BPOM Regulation No. 11 of 2026 on Food Packaging, which expands the list of approved food-contact substances and recognizes a broader range of permissible functions for those substances. The new regulation, which revokes BPOM Regulation No. 20 of 2019, reflects developments in packaging technology and materials science. Although the new regulation provides more advantages to business actors by adding more food contact substances to the approved list for use in food packaging, there are more stringent rules and restrictions for testing. One of the most significant changes is a comprehensive migration-testing framework that sets out requirements for packaging materials, testing conditions, food simulants, and specific migration limits. Overall and Specific Migration Under BPOM Regulation No. 20 of 2019, migration requirements were primarily set out within the lists of approved food-contact substances and packaging materials. BPOM Regulation No. 11 of 2026 instead expressly requires packaging materials that come into direct contact with food to meet both overall and specific migration limits. These are defined as follows: Overall migration: The total quantity of all substances that migrate from the packaging, regardless of whether the substances are hazardous or nonhazardous to health. Specific migration: The quantity of a particular identified substance known to be hazardous to health that migrates from the packaging. Stricter Limits on Heavy Metals The overall migration limit for plastic packaging remains unchanged under both regulations at 60 mg/kg or 10 mg/dm². However, the new regulation introduces significant changes to the regulation of heavy metals. Under the 2019 regulation, four heavy metals—lead, cadmium, chromium VI, and mercury—were subject to a single combined limit of 1 mg/kg. The 2026 regulation, however, requires each heavy metal to meet its own individual specific migration limit, adds arsenic as
Read More
September 7, 2026
Indonesia’s Constitutional Court (Mahkamah Konstitusi) has reinstated a key provision limiting pharmaceutical patent protection, signaling a renewed commitment to balancing patent rights with public access to medicines. In its ruling to Case No. 255/PUU-XXIII/2025, the court partially granted a petition for judicial review of Law No. 65 of 2024, which had amended the country’s Patent Law, and ordered the restoration of a provision that had excluded certain pharmaceutical inventions from patentability. The decision took effect immediately upon its pronouncement at the court’s plenary session on August 28, 2026. Background The petition challenged the removal of article 4(f) from Law No. 13 of 2016 concerning Patents (Patent Law), as amended by Law No. 65 of 2024. Article 4(f) had excluded from patentability certain inventions relating to new uses of known substances. The petitioners argued that removing this provision would open the door to patent protection for second medical use inventions and facilitate patent evergreening—practices that can extend exclusivity periods, delay generic market entry, and reduce public access to affordable medicines. The petitioners included several patient advocacy and public-interest organizations: the Indonesian Dialysis Patients Community Association, the Indonesian Association of Drug Abuse Victims (PKNI), the Indonesian Pulmonary Hypertension Foundation (YHPI), the Rekat Peduli Indonesia Foundation, and the Indonesian Positive Women’s Association (IPPI), along with the Indonesia for Global Justice Association and four individual petitioners. The petitioners also challenged the constitutionality of the phrase “interested party” in article 70(1) of the Patent Law, arguing that it should be construed expressly to clarify who has standing to appeal a decision to grant a patent before the Board of Patent Appeal, and to allow a broader range of parties—such as patent holders, licensees, consumer organizations, prosecutors, aggrieved third parties, and others who may suffer direct or indirect harm from the grant of a patent—to
Read More